Platelets for cancer treatment and drug delivery
- PMID: 35218523
- DOI: 10.1007/s12094-021-02771-x
Platelets for cancer treatment and drug delivery
Abstract
Extensive research is currently being conducted into a variety of bio-inspired biomimetic nanoparticles (NPs) with new cell simulation functions across the fields of materials science, chemistry, biology, physics, and engineering. Cells such as erythrocytes, platelets, and stem cells have been engineered as new drug carriers. The platelet-derived drug delivery system, which is a new targeted drug delivery system (TDDS), can effectively navigate the blood circulatory system and interact with the complex tumor microenvironment; it appears to outperform traditional anticancer drugs; hence, it has attracted considerable research interest. In this review, we describe innovative studies and outline the latest progress regarding the use of platelets as tumor targeting and drug delivery vehicles; we also highlight opportunities and challenges relevant to the manufacture of tumor-related platelet TDDSs.
Keywords: Biological carrier; Cancer; Combination therapy; Drug delivery technology; Platelet.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
References
-
- Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab′ fragments and single chain Fv. J Control Release. 2008;1:50–8. - DOI
-
- Yin Q, Shen J, Zhang Z, et al. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev. 2013;13–14:1699–715. - DOI
-
- Kolhatkar RB, Swaan P, Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly (amidoamine) dendrimers. Pharm Res. 2008;7:1723–9. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
